Myotonic Dystrophy Type 1 (DM1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. DM1 is a dominant disorder characterized by multisystemic clinical features affecting skeletal muscle, heart, and the nervous and endocrine systems.
·
The prevalence varies by region and is most
common in individuals of European descent. According to Thelansis disease
modeling data, results of literature reviews, surveys, and registry analyses
combined prevalence reported as 1 in 8,000 (12.5 per 100,000).
·
Myotonic Dystrophy Type 1 (DM1) is caused by
the expansion of a CTG repeat in the 3' noncoding region of the DMPK gene on
chromosome 19q13.3, which codes for the myotonic dystrophy protein kinase.
·
Normal individuals have between 5 and 37
repeats, but symptomatic patients typically have > 50 repeats.
DM1 is categorized into four subtypes:
congenital, childhood, classic, and minimal/late-onset.
Thelansis’s “Myotonic Dystrophy Type 1
(DM1) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Myotonic
Dystrophy Type 1 (DM1) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Myotonic Dystrophy Type 1 (DM1) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Myotonic Dystrophy Type 1 (DM1) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment